NCT04322760View on ClinicalTrials.gov

Lidocaine 5% Patch Supplementation to Intra-articular Bupivacaine Dexmedetomidine After Arthroscopic Knee Surgery

NACompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 1, 2016

Primary Completion Date

November 30, 2017

Study Completion Date

December 1, 2017

Conditions
DexmedetomidineLidocaine 5% PatchArthroscopic Knee SurgeryIntra-articular
Interventions
DRUG

Lidocaine 5% patch with Dexmedetomidine Bupivacaine

10 ml 0.5 % Bupivacaine and 1µg/kg Dexmedetomidine diluted in 10 ml saline was injected intra-articularly through one of the arthroscopic ports after the end of the surgery under complete aseptic technique and a patch of lidocaine 5% was applied to the skin between the arthroscopic ports

DRUG

Dexmedetomidine Bupivacaine

10 ml 0.5 % Bupivacaine and 1µg/kg Dexmedetomidine diluted in 10 ml saline was injected intra-articularly through one of the arthroscopic ports after the end of the surgery under complete aseptic technique without a patch of lidocaine 5%

All Listed Sponsors
lead

Tanta University

OTHER

NCT04322760 - Lidocaine 5% Patch Supplementation to Intra-articular Bupivacaine Dexmedetomidine After Arthroscopic Knee Surgery | Biotech Hunter | Biotech Hunter